This study looks at how well sonrotoclax combined with obinutuzumab works compared to venetoclax with rituximab. It also examines how sonrotoclax with rituximab measures against venetoclax with rituximab. The goal is to find out which combination helps more in treating adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or didn’t respond to previous treatments. Safety of the treatments will also be checked.
The trial's ID is NCT06943872. This is a Phase 3 study, which means it is looking at how well the treatments work and their safety. It is regulated by the FDA and aims to include about 630 participants.
Who can join
Adults aged 18 and older can join this study. It's open to both men and women with a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma, who have had at least one prior treatment. Some health conditions may exclude participants, like certain heart diseases or active central nervous system involvement. The study team will confirm who is eligible to join.
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed in groups by chance. There are four groups:
Group A receives sonrotoclax and obinutuzumab.
Group B receives sonrotoclax and rituximab.
Group C gets sonrotoclax and obinutuzumab with treatment based on minimal residual disease evaluation.
Group D receives venetoclax and rituximab. Everyone will receive the assigned treatment.
Where
This trial is enrolling at 34 locations. Recruiting sites are listed first.
Elected to the National Academy of Medicine. Treats leukemia and myelodysplastic syndrome. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.